Scholarlink

<p>HIV-associated diffuse large B-cell lymphoma (DLBCL) is a rare type of lymphoma with poor prognosis. β2-microglobulin (β2-M) is elevated in people living with HIV, but its prognostic significance in HIV-associated DLBCL remains unclear. We retrospectively analyzed 89 HIV-associated DLBCL patients treated at Chongqing University Cancer Hospital between October 2012 and December 2023. The primary outcome was the clinical overall survival (OS) rate. The optimal cut-off value of β2-M was determined to be 5&#xa0;mg/L. Compared to the low serum β2-M group (&lt; 5&#xa0;mg/L), patients in the high serum β2-M group (≥ 5&#xa0;mg/L) had a higher International Prognostic Index (IPI)/ age adjusted IPI (aaIPI) score, more B symptoms, lower CD4<sup>+</sup>T cell counts, and higher lactate dehydrogenase (LDH) level. Patients in high group exhibited poorer OS, with 1-, 3-, and 5-year OS rates of 33.4%, 22.8%, and 18.2%, respectively. Multivariate Cox regression analysis identified serum β2-M ≥ 5&#xa0;mg/L as an independent risk factor influencing OS of this patient group. Moreover, CD8<sup>+</sup>T cell count &lt; 392 cells/µL, LDH ≥ 375 U/L, and non-receipt of standard treatment were also independent risk factors. Receiver operating characteristic curve analysis demonstrated that these four independent risk factors accurately predicted survival in HIV-associated DLBCL. 5&#xa0;mg/L threshold for serum β2-M was associated with poor OS in HIV-associated DLBCL, indicating it could serve as a novel biomarker for assessing their prognosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Serum β2-microglobulin level is associated with the survival of HIV-associated diffuse large B-cell lymphoma: a retrospective study from China

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月7日

查看全文
  • Xinyi Tang,
  • Tingting Jiang,
  • Bingling Guo,
  • Jun Liu,
  • Chaoyu Wang,
  • Yakun Zhang,
  • Shuang Chen,
  • Yu Peng,
  • Xiaomei Zhang,
  • Jun Li,
  • Yao Liu,
  • Zailin Yang

摘要

HIV-associated diffuse large B-cell lymphoma (DLBCL) is a rare type of lymphoma with poor prognosis. β2-microglobulin (β2-M) is elevated in people living with HIV, but its prognostic significance in HIV-associated DLBCL remains unclear. We retrospectively analyzed 89 HIV-associated DLBCL patients treated at Chongqing University Cancer Hospital between October 2012 and December 2023. The primary outcome was the clinical overall survival (OS) rate. The optimal cut-off value of β2-M was determined to be 5 mg/L. Compared to the low serum β2-M group (< 5 mg/L), patients in the high serum β2-M group (≥ 5 mg/L) had a higher International Prognostic Index (IPI)/ age adjusted IPI (aaIPI) score, more B symptoms, lower CD4+T cell counts, and higher lactate dehydrogenase (LDH) level. Patients in high group exhibited poorer OS, with 1-, 3-, and 5-year OS rates of 33.4%, 22.8%, and 18.2%, respectively. Multivariate Cox regression analysis identified serum β2-M ≥ 5 mg/L as an independent risk factor influencing OS of this patient group. Moreover, CD8+T cell count < 392 cells/µL, LDH ≥ 375 U/L, and non-receipt of standard treatment were also independent risk factors. Receiver operating characteristic curve analysis demonstrated that these four independent risk factors accurately predicted survival in HIV-associated DLBCL. 5 mg/L threshold for serum β2-M was associated with poor OS in HIV-associated DLBCL, indicating it could serve as a novel biomarker for assessing their prognosis.